Shah-Khan MG et al., 2012-05-09: Mayo Clinic surgical review of the FDA 2011 announcement and methylene blue pharmacokinetics concluding that low-dose methylene blue dye for lymphatic mapping likely carries very little risk of serotonin neurotoxicity. It is a commentary/review, not a new study, and it addresses lymphatic mapping rather than oral dosing.
The authors conclude that the use of methylene blue dye at low doses for lymphatic mapping likely carries very little risk for serotonin neurotoxicity
Shah-Khan MG et al., 2012-05-09: Mayo Clinic surgical review of the FDA 2011 announcement and methylene blue pharmacokinetics concluding that low-dose methylene blue dye for lymphatic mapping likely carries very little risk of serotonin neurotoxicity. It is a commentary/review, not a new study, and it addresses lymphatic mapping rather than oral dosing. Study type: review.
